Polar Capital Funds PLC - Biotechnology Fund S Inc (EUR)

Register to Unlock Ratings
Performance History31/10/2024
Growth of 1,000 (GBP) Advanced Graph
Polar Capital Funds PLC - Biotechnology Fund S Inc (EUR)
Fund36.75.94.910.08.4
+/-Cat10.814.912.711.37.0
+/-B’mrk3.85.62.42.72.6
 
Key Stats
NAV
20/11/2024
 EUR 46.66
Day Change 0.80%
Morningstar Category™ Sector Equity Biotechnology
ISIN IE00BF23BX13
Fund Size (Mil)
20/11/2024
 USD 1926.08
Share Class Size (Mil)
20/11/2024
 USD 15.22
Max Initial Charge 5.00%
Ongoing Charge
30/06/2024
  0.87%
Investment Objective: Polar Capital Funds PLC - Biotechnology Fund S Inc (EUR)
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation.
Returns
Trailing Returns (GBP)20/11/2024
YTD8.78
3 Years Annualised7.68
5 Years Annualised14.69
10 Years Annualised15.04
12 Month Yield -
Dividend Paying Frequency Annually
Management
Manager Name
Start Date
David Pinniger
31/10/2013
Gareth Powell
31/10/2013
Inception Date
31/10/2013
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology NR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNo
HedgingNo
OtherNot Specific
Portfolio Profile for  Polar Capital Funds PLC - Biotechnology Fund S Inc (EUR)30/09/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock99.060.0099.06
Bond0.000.000.00
Property0.000.000.00
Cash0.940.000.94
Other0.000.000.00
Top 5 Regions%
United States68.16
Europe - ex Euro15.14
Eurozone7.58
United Kingdom6.08
Canada3.05
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
argenx SEHealthcareHealthcare7.05
Amgen IncHealthcareHealthcare6.29
Zealand Pharma ASHealthcareHealthcare5.23
Alnylam Pharmaceuticals IncHealthcareHealthcare4.29
Vertex Pharmaceuticals IncHealthcareHealthcare4.23
Polar Capital Funds PLC - Biotechnology Fund S Inc (EUR)

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures